Next Article in Journal
Making of Viral Replication Organelles by Remodeling Interior Membranes
Next Article in Special Issue
Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246
Previous Article in Journal
Detecting Retroviral Sequences in Chronic Fatigue Syndrome
Previous Article in Special Issue
Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections
Review

Development of ST-246® for Treatment of Poxvirus Infections

SIGA Technologies, 4575 SW Research Way, Corvallis, OR 97333, USA
*
Author to whom correspondence should be addressed.
Viruses 2010, 2(11), 2409-2435; https://doi.org/10.3390/v2112409
Received: 18 September 2010 / Revised: 26 October 2010 / Accepted: 26 October 2010 / Published: 3 November 2010
(This article belongs to the Special Issue Antivirals Against Poxviruses)
ST-246 (Tecovirimat) is a small synthetic antiviral compound being developed to treat pathogenic orthopoxvirus infections of humans. The compound was discovered as part of a high throughput screen designed to identify inhibitors of vaccinia virus-induced cytopathic effects. The antiviral activity is specific for orthopoxviruses and the compound does not inhibit the replication of other RNA- and DNA-containing viruses or inhibit cell proliferation at concentrations of compound that are antiviral. ST-246 targets vaccinia virus p37, a viral protein required for envelopment and secretion of extracellular forms of virus. The compound is orally bioavailable and protects multiple animal species from lethal orthopoxvirus challenge. Preclinical safety pharmacology studies in mice and non-human primates indicate that ST-246 is readily absorbed by the oral route and well tolerated with the no observable adverse effect level (NOAEL) in mice measured at 2000 mg/kg and the no observable effect level (NOEL) in non-human primates measured at 300 mg/kg. Drug substance and drug product processes have been developed and commercial scale batches have been produced using Good Manufacturing Processes (GMP). Human phase I clinical trials have shown that ST-246 is safe and well tolerated in healthy human volunteers. Based on the results of the clinical evaluation, once a day dosing should provide plasma drug exposure in the range predicted to be antiviral based on data from efficacy studies in animal models of orthopoxvirus disease. These data support the use of ST-246 as a therapeutic to treat pathogenic orthopoxvirus infections of humans.
Keywords: Smallpox; ST-246; Tecovirimat; orthopoxvirus; p37; egress inhibitor; antiviral drug Smallpox; ST-246; Tecovirimat; orthopoxvirus; p37; egress inhibitor; antiviral drug
MDPI and ACS Style

Jordan, R.; Leeds, J.M.; Tyavanagimatt, S.; Hruby, D.E. Development of ST-246® for Treatment of Poxvirus Infections. Viruses 2010, 2, 2409-2435. https://doi.org/10.3390/v2112409

AMA Style

Jordan R, Leeds JM, Tyavanagimatt S, Hruby DE. Development of ST-246® for Treatment of Poxvirus Infections. Viruses. 2010; 2(11):2409-2435. https://doi.org/10.3390/v2112409

Chicago/Turabian Style

Jordan, Robert; Leeds, Janet M.; Tyavanagimatt, Shanthakumar; Hruby, Dennis E. 2010. "Development of ST-246® for Treatment of Poxvirus Infections" Viruses 2, no. 11: 2409-2435. https://doi.org/10.3390/v2112409

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop